Santos David A 4
4 · RIGEL PHARMACEUTICALS INC · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Rigel (RIGL) EVP David Santos Receives Stock Option Award
What Happened
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL), had a performance-based stock option covering 7,394 shares reported as acquired (derivative) on June 17, 2026. The option carries an exercise price of $22.49 per share (the closing price on the original grant date), meaning it would cost roughly $166,291 to exercise all options. The filing reports the acquisition at $0.00 because this Form 4 records the vesting/award event (not an exercise or cash purchase).
Key Details
- Transaction date: June 17, 2026; Form 4 filed June 22, 2026.
- Reported transaction: Award/Acquisition (derivative) of 7,394 shares at $0.00.
- Option exercise price: $22.49 per share (total exercise cost ≈ $166,291).
- Footnotes: Option was originally granted Jan 29, 2025 with a performance-based vesting condition; the performance metric was satisfied and the option fully vested on June 17, 2026.
- Shares owned after transaction: Not disclosed in the provided Form 4.
Context
- This filing documents vesting of a performance-based option (a derivative award), not an immediate cash purchase or sale of shares. Santos has the right to exercise the options at $22.49 per share going forward; exercising, selling, or holding would trigger separate filings.
- Vesting awards are routine compensation events and do not by themselves indicate whether the insider will buy or sell shares.
Insider Transaction Report
Form 4
Santos David A
EVP, Chief Commercial Officer
Transactions
- Award
Employee Stock Option (right to buy)
[F1][F2]2026-06-17+7,394→ 7,394 totalExercise: $22.49Exp: 2035-01-29→ Common Stock (7,394 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- [F2]The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Signature
/s/ Raymond Furey (Attorney-in-Fact)|2026-06-22